Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies
SAN DIEGO, May 20, 2013 /PRNewswire/ -- Dr. Gerald Zon, noted scientist in the field of nucleic acid research, recently launched a new blog in conjunction with TriLink BioTechnologies. The blog, Zone In with Zon (zon.trilinkbiotech.com), focuses on what's trending in the field of nucleic acids. Blog posts include interviews with industry thought leaders, discussions of research presented at conferences and meetings, reviews of current publications and more.
Dr. Zon (PhD Princeton University 1971) developed automated synthesis of DNA analogs at the National Institutes of Health, and later at Applied Biosystems (ABI). In 1992 he co-founded ABI spin-off Lynx Therapeutics, an antisense company. He returned to ABI in 1999 to head DNA sequencing R&D, and then worked on novel methods for DNA sequencing as a Research Fellow at Life Technologies. In 2006, Dr. Zon was admitted as a Fellow of The Royal Society of Chemistry in the UK. At TriLink BioTechnologies since 2011, he is now Director of Business Development. Dr. Zon has published over 260 papers and patents, and is a longtime member of the Editorial Board for Analytical Biochemistry.
TriLink manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp™ PCR products for the diagnostic and OEM markets. In addition, custom chemistry, long RNA transcript synthesis and contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 50 scientists and other professionals. For more information about the firm and products, visit our web site at www.trilinkbiotech.com.
SOURCE TriLink BioTechnologies